
Kala Pharmaceuticals KALA
$ 0.17
1.35%
Quarterly report 2025-Q3
added 11-19-2025
Kala Pharmaceuticals Total Liabilities 2011-2026 | KALA
Annual Total Liabilities Kala Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.2 M | 48.4 M | 67.8 M | 123 M | 122 M | 125 M | 116 M | 26.5 M | 134 M | 65.1 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | 26.5 M | 87 M |
Quarterly Total Liabilities Kala Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.7 M | 39.3 M | 42.5 M | 43.2 M | 47.2 M | 47.9 M | 46.4 M | 48.4 M | 49.9 M | 49 M | 48.8 M | 67.8 M | 86.7 M | 117 M | 117 M | 123 M | 132 M | 131 M | 120 M | 122 M | 122 M | 122 M | 122 M | 125 M | 125 M | 125 M | 125 M | 116 M | 116 M | 116 M | 116 M | 26.9 M | 26.9 M | 26.9 M | 26.9 M | 15.7 M | 15.7 M | 15.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 15.7 M | 78.8 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
707 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
7.24 M | - | 10.36 % | $ 9.8 M | ||
|
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | ||
|
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | ||
|
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Axcella Health
AXLA
|
14.8 M | - | -16.42 % | $ 249 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | ||
|
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
425 M | - | - | $ 546 M | ||
|
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | ||
|
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | ||
|
CASI Pharmaceuticals
CASI
|
30.3 M | - | - | $ 35.4 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
ChemoCentryx
CCXI
|
140 M | - | - | $ 3.74 B | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Завод ДИОД
DIOD
|
195 M | - | - | - | ||
|
Фармсинтез
LIFE
|
1.04 B | - | - | - | ||
|
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | ||
|
Chimerix
CMRX
|
19.7 M | - | - | $ 756 M | ||
|
Teligent, Inc.
TLGT
|
198 M | - | -13.85 % | $ 16.1 M | ||
|
AbbVie
ABBV
|
97.3 B | $ 208.7 | -0.07 % | $ 369 B | ||
|
Calithera Biosciences
CALA
|
15.7 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
11.1 M | - | -3.03 % | $ 260 M | ||
|
Viela Bio, Inc.
VIE
|
47.4 M | - | - | $ 2.91 B | ||
|
AbCellera Biologics
ABCL
|
390 M | $ 3.52 | -0.14 % | $ 1.05 B |